

12/21/01

10023584 122101

9474 U.S. PTO  
10/023584

12/21/01

Please type a sign (+) inside this box + PTO/SB/05 (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0092  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	PF112P1D2
First Inventor	ROSEN et al.
Title	Human Vascular Endothelial Growth Factor 2
Express Mail Label No.	

**APPLICATION ELEMENTS**  
See MPEP chapter 600 concerning utility patent application contents.**ADDRESS TO:** Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17) (in duplicate)  
(Submit an original, and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 45]  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 14] (Figs. 1A-9)
5. ☒ Declaration [Total Pages 4]
  - a. ☐ Newly executed (original or copy)
  - b. ☒ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17 completed)
  - i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☒ Application Data Sheet. See 37 CFR 1.76. (3 pages)

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a. ☐ Computer Readable Form (CRF)
  - b. Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☒ paper (8 pages)
  - c. ☐ Statements verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

9. ☒ Assignment Recordation Papers (cover sheet & documents (6 pp.))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☒ Information Disclosure Statement/Form PTO/SB/08  
☒ Copies of References AA-FU and five (5) Statutory Declarations and accompanying exhibits
13. ☒ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)  
(should be specifically itemized)
15. ☐ Certified copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☒ **Other:** (a) Request Under 37 C.F.R. 1.821(e); and (b) Copy of Revocation by Assignee of Entire Interest/Revocation of Prior Power of Attorney from Appl. No. 08/465,968

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

<input type="checkbox"/> Continuation	<input checked="" type="checkbox"/> Divisional	<input type="checkbox"/> Continuation-in-Part (CIP)	of prior application No: <u>08/465,968</u> ; filed <u>June 6, 1995</u>
Prior application information: Examiner <u>Saoud, C.</u>			Group/Art Unit: <u>1646</u>

**18. CORRESPONDENCE ADDRESS**☒ Customer Number or Bar Code Label 22195 or ☐ Correspondence address below

NAME					
ADDRESS					
CITY	STATE	ZIP CODE			
COUNTRY	TELEPHONE	FAX			
NAME (Print/Type)	Michele M. Wales		Registration No. (Attorney/Agent)	43,975	
SIGNATURE	<u>Michele M. Wales</u>		Date	<u>12/21/01</u>	

Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rosen et al.

Application Serial No.: Unassigned

Art Unit: unassigned

Filed: Herewith

Examiner: unassigned

For: **Human Vascular Endothelial Growth  
Factor 2**

Attorney Docket No.: PF112P1D2

REQUEST UNDER 37 C.F.R. § 1.821(e)

Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir :

The above-identified patent application is a divisional of application Serial No. 08/465,968, filed June 6, 1995. The sequence listing of the instant application is identical to the sequence content of the computer readable sequence listing filed in connection with Application Serial No. 08/465,968, on December 9, 1998.

In accordance with 37 C.F.R. § 1.821(e), please use the computer readable form filed on December 9, 1998 in connection with application Serial No. 08/465,968 as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the original and Substitute Sequence Listing is included in the specification of the instant application filed herewith. Applicants hereby certify that the paper copy of the Substitute Sequence Listing filed herewith and the computer readable sequence listing filed on December 9, 1998 in connection with application Serial No. 08/465,968 are the same and do not include new matter.

Respectfully submitted,

Dated: 12/21/01

  
Michele M. Wales (Reg. No. 43,975)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 610-5772 (telephone)

Enclosure  
MMW/AKR/lcc

1002584-12101  
F01221-18523001